🔗 Share this article

Given that America continues making historic adjustments to its immunization guidelines, one figure has surfaced unexpectedly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccinations during the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her brief tenure at the FDA.

Scheduled Shifts to Childhood Vaccine Schedule

Agency leaders were set to reveal major revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would put the US at odds with many the world with no evidence for public health gain. The announcement has been postponed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is set to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

A Shift at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more like the Danish model, a country with comprehensive healthcare and a number of inhabitants about the size of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Expertise

The appointee has no obvious track record in drug development, oversight or leadership, which has been standard for former heads of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She lacks background in drug approvals.”

Past commissioners of CBER would “understand regulatory frameworks and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an immense workload at the agency, Woodcock pointed out.

“The public just pays attention on the innovative therapies, but the generic drug division clears numerous generic drugs. There’s a biosimilars program, over-the-counter program and other areas, and each of these have to be managed,” Dr. Woodcock said. “The area you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a significant administrative component to the job, which oversees more than 5,000 employees. “It’s a huge administrative position, if you execute it properly,” Woodcock concluded.

Agency Reaction and Contentious Programs

In response to questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among FDA leaders on vaccines, a spokesperson stated that the “questions are based on incorrect presumptions”.

“Her experience matches the functions of her position,” the representative stated, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the agency head's new fast-track approval initiative, a disputed expedited medication authorization process that apparently worried her predecessors. “How are these therapies being picked for this fast-track system? Who makes the choices?” Dr. Howard said. “There is a lot of confidentiality happening at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed rules of all drugs, aside from immunizations.”

Documented History on Vaccines

With vaccines, Dr. Høeg has a clearer, if troubling, history, Howard said. She published a analysis using non-validated crowd-sourced reports to assess the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the current administration included revising regulations for new vaccines and halting “optional” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has according to sources suggested preventing adolescent males from getting COVID-19 vaccinations.

“She’s an thorough ideologue who starts off with her preconceived notions and works backwards to fit the science in a extremely misleading, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|